首页|膀胱尿路上皮癌HER2表达及临床病理分析

膀胱尿路上皮癌HER2表达及临床病理分析

扫码查看
目的 探讨膀胱尿路上皮癌(bladder urothelial carcinoma,BUC)中HER2的表达情况,并分析其临床意义.方法 收集膀胱非浸润性低级别BUC 27例、非浸润性高级别BUC 5例、浸润性高级别BUC 60例,采用免疫组化MaxVision法法检测各组织样本中HER2蛋白的表达,并分析HER2表达与临床病理特征的关系.通过GEPIA数据库或直接在肿瘤基因组图谱(The Cancer Genome Atlas,TCGA)中分析HER2(ERBB2)表达与BUC的关系.结果 浸润性高级别BUC中HER2 2+/3+表达率(26.67%,16/60)显著高于非浸润性低级别BUC(7.41%,2/27)和非浸润性高级别BUC(0,0/5)(P<0.05).多灶性浸润性高级别BUC中HER2 2+/3+表达率(75.00%,6/8)显著高于单灶性患者(19.23%,10/52)(P<0.05).各组织学亚型中HER2 2+/3+表达率差异有统计学意义(P<0.05),其中普通型为30%(6/20)、腺样分化型为57.14%(4/7)、微乳头型为66.67%(4/6)、浆细胞样型为100.00%(2/2),余亚型均为0/1+.HER2表达与其他临床病理特征均无明显相关性(P>0.05).GEPIA数据库中,BUC肿瘤组织中HER2(ERBB2)表达高于正常组织(P>0.05),HER2(ERBB2)高表达患者的总生存期(overall survival,OS)低于HER2(ERBB2)低表达(P>0.05);对TCGA数据进行Cox单因素分析显示:年龄、分期、T和N越高的患者OS较短.结论 浸润性高级别BUC中HER2 2+/3+表达率高于非浸润性低级别和高级别BUC,并与肿瘤个数、组织学亚型密切相关,提示结合HER2表达状态、肿瘤个数和组织学亚型或有助于筛选出可能从HER2靶向治疗中获益的浸润性高级别BUC患者.
Analysis HER2 expression and clinicopathologic analysis in urothelial carcinoma of the bladder
Purpose To investigate the protein expression of human epidermal growth factor receptor 2(HER2)in bladder urothelial carcinoma(BUC)tissues and to analyze its clinical significance.Methods 27 cases of non-invasive low-grade BUC,5 cases of non-invasive high-grade BUC and 60 cases of invasive high-grade BUC of the bladder were collected.The im-munohistochemical method(IHC)detection technique was used to detect the expression of HER2 protein in each tissue sample and analyze the relationship between the expression of HER2 and clinicopathological characteristics of BUC.The relationship be-tween HER2(ERBB2)expression and BUC was analyzed indi-rectly through the GEPIA database or directly in the TCGA(The Cancer Genome Atlas).Results The HER2 2+/3+expres-sion rate of invasive high-grade BUC(26.67%,16/60)was significantly higher than non-invasive low-grade BUC(7.41%,2/27)and non-invasive high-grade BUC(0,0/5)(P<0.05).The 2+/3+expression rate of HER2 of multifocal in-vasive high-grade BUC was 75.00%(6/8),which was signifi-cantly higher than that of unifocal invasive high-grade BUC,which was 19.23%(10/52)(P<0.05).There was a signifi-cant difference in the expression of HER2 in the histological sub-types(P<0.05),with the 2+/3+positive rate of the usual type being 30%(6/20),with adenoid differentiation type was 57.14%(4/7),micropapillary type was 66.67%(4/6),plasma cell-like type was 100.00%(2/2),and the rest of the subtypes were negatively expressed.There was no statistically significant relationship between HER2 expression and other clin-icopathologic features(P>0.05).In the TGGA data,HER2(ERBB2)expression in BUC tumor tissues was higher than that in normal tissues(P>0.05),and the overall survival(OS)of patients with high HER2(ERBB2)expression was lower than that of patients with low HER2(ERBB2)expression(P>0.05);the results of the Cox univariate analysis showed that OS was shorter in patients with higher age,Stage,T and N.The a-bove significantly different factors were included in Cox multifac-torial analysis,which showed that age,Stage,T and N were in-dependent prognostic factors for BUC.Conclusion The 2+/3+expression rate of HER2 in invasive high-grade UBC was higher than that in non-invasive low-grade and non-invasive high-grade BUC and was closely associated with the number of tumor and histological subtypes.The HER2 expression status combined with the number of tumor and histological subtypes may be helpful in screening patients for potential HER2-targeted therapies effective in invasive high-grade BUC.

bladder urothelial carcinomainvasive high-grade uroepithelial carcinoma of the bladderHER2clinicopathologyimmunohistochemistry

尹玉、仲坤、李雪、罗文武、蒋俊兰

展开 >

安徽医科大学第一附属医院病理科,合肥 230022

安徽医科大学基础医学院病理学教研室,合肥 230032

安徽理工大学第一附属医院病理科,淮南 232007

膀胱尿路上皮癌 浸润性高级别尿路上皮癌 HER2 临床病理 免疫组织化学

2024

临床与实验病理学杂志
安徽医科大学,中华医学会安徽分会

临床与实验病理学杂志

CSTPCD北大核心
影响因子:0.776
ISSN:1001-7399
年,卷(期):2024.40(4)
  • 1
  • 4